Advertisement

Advertisement
Breast Cancer
Genomics/Genetics

Genetic Alterations Associated With Interval Breast Cancer Diagnosis

In a Swedish study reported in JAMA Oncology, Rodriguez et al identified characteristics of interval breast cancers—those diagnosed between two screening examinations...

Breast Cancer
Genomics/Genetics

Does Risk-Reducing Mastectomy Reduce the Risk of Breast Cancer—and Mortality?

Investigators have found that risk-reducing mastectomy decreases the risk of receiving a breast cancer diagnosis and the likelihood of mortality in female patients...

CNS Cancers

TBI and Risk of Brain Cancer in Veterans of the Iraq and Afghanistan Wars

In a retrospective cohort study reported in JAMA Network Open, Stewart et al found that U.S. veterans of the Iraq and Afghanistan wars with moderate/severe or penetrating...


Advertisement
Bladder Cancer

Final Results of the POUT Trial: Adjuvant Chemotherapy vs Surveillance After Nephroureterectomy for Upper Tract Urothelial Cancer

As reported in the Journal of Clinical Oncology by Alison Jane Birtle, MD, MBBS, MRCP, FRCR, and colleagues, final results of the UK-based phase III POUT trial showed survival...

Lung Cancer

Perioperative Tislelizumab Plus Chemotherapy in Resectable NSCLC

In patients with resectable non–small cell lung cancer (NSCLC), perioperative treatment with the checkpoint inhibitor tislelizumab plus platinum-doublet chemotherapy...

Advertisement
Advertisement





Prostate Cancer
Issues in Oncology

Peter C. Black, MD, on Prostate Cancer Health-Care Disparities: Expert Perspective

Solid Tumors
Genomics/Genetics
Immunotherapy

Pertuzumab/Trastuzumab Demonstrates Activity in Tissue-Agnostic Trial for Patients With HER2-Positive Tumors

Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with KRAS mutations....

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Breast Cancer

Priya Rastogi, MD, on Breast Cancer: Predicting the Benefit of Extended Letrozole Therapy

Breast Cancer

Efficacy of Platinum Chemotherapy vs Capecitabine for Basal-Like Triple-Negative Breast Cancer

About 80% of triple-negative breast cancers are classified as the subtype basal-like. Typically, patients with triple-negative breast cancer receive chemotherapy before surgery. The presence of residual cancer in the breast after chemotherapy signals a higher likelihood that the cancer will...

Multiple Myeloma
Immunotherapy

APOLLO Trial: Addition of Subcutaneous Daratumumab to Pomalidomide/Dexamethasone in Previously Treated Patients With Multiple Myeloma

As reported in The Lancet Oncology by Meletios A. Dimopoulos, MD, and colleagues, the phase III APOLLO trial has shown significantly improved progression-free survival with the addition of subcutaneous daratumumab to pomalidomide/dexamethasone in patients with previously treated multiple myeloma....

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Colorectal Cancer
Immunotherapy
Genomics/Genetics

Cathy Eng, MD, on Colorectal Cancer: FOLFOXIRI, Cetuximab, and Bevacizumab as First-Line Treatment

Breast Cancer
Immunotherapy

Adjuvant Trastuzumab Emtansine vs Paclitaxel/Trastuzumab in Stage I HER2-Positive Breast Cancer

In the phase II ATEMPT trial reported in the Journal of Clinical Oncology, Sara M. Tolaney, MD, MPH, and colleagues found that adjuvant trastuzumab emtansine (T-DM1) resulted in “excellent” invasive disease–free survival but did not reduce clinically relevant toxicity compared with...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...

Twitter